PLANNING COMMITTEE DISCLOSURES

This non-accredited learning activity is financially supported by Amgen Canada and is for healthcare professionals only.
This content was developed in concert with the scientific planning committee members.

Planning Committee MemberDisclosures
Jonathan Adachi, MD, FRCPC
Professor Department of Medicine
McMaster University

Advisory Board/Speaker's Bureau: Amgen
Speaker/Consultant: Amgen
Grants/Clinical Trials: Abbvie, Amgen, Celgene, Janssen, Pfizer, Radius, Sanofi, UCB

Jacques Brown, MD, FRCPC
Clinical Professor Department of Medicine
Laval University

Advisory Board/Speaker's Bureau: Amgen
Speaker/Consultant: Amgen, Janssen, Orimed, Servier
Grants/Clinical Trials: Mereo Biopharma, Radius Health, Servier

Jeff Habert, MD, CCFP, FCFP
Assistant Professor
Department of Family and Community Medicine
University of Toronto

Advisory Board/Speaker's Bureau: Allergan, Amgen, Astra- Zeneca, Bayer, BMS, Boehringer, Eli-Lilly, HLS, Janssen, Lundbeck, Novo- Nordisk, Otsuka, Pfizer, Purdue, Roche, Sanofi, Servier
Speaker/Consultant: CCRN, CHRC, CPD Network, CTC, Master Clinician Alliance, MDBriefcase, Bausch, Thrombosis Canada
Grants/Clinical Trials: N/A


Learning Objectives

By the end of the program participants will be able to:

  • Describe the mechanisms of action of treatments for osteoporosis and how they relate to the reversibility of each specific therapy
  • Summarize the data around treatment interruption and long-term use of treatment for osteoporosis
  • Evaluate/assess which types of patients should not interrupt osteoporosis treatment based on fracture risk

cpdisup